Solid Tumors Challenges and New Insights of CAR T Cell Engineering
- PMID: 31161552
- DOI: 10.1007/s12015-019-09901-7
Solid Tumors Challenges and New Insights of CAR T Cell Engineering
Abstract
Adoptive cell therapy using CAR T cells has emerged as a novel treatment strategy with promising results against B cell malignancies; however, CAR T cells have not shown much success against solid malignancies. There are several obstacles which diminish the efficacy of CAR T cells, but the immunosuppressive tumor microenvironment (TME) of the tumor stands out as the most important factor. TME includes Tumor-Associated Stroma, Immunosuppressive cells and cytokines, tumor hypoxia and metabolism, and Immune Inhibitory Checkpoints which affect the CAR T cell efficacy and activity in solid tumors. A precise understanding of the TME could pave the way to engineer novel modifications of CAR T cells which can overcome the immunosuppressive TME. In this review, we will describe different sections of the TME and introduce novel approaches to improve the CAR T cells potential against solid tumors based on recent clinical and preclinical data. Also, we will provide new suggestions on how to modify CARs to augment of CAR T cells efficacy. Since there are also some challenges beyond the TME that are important for CAR function, we will also discuss and provide data about the improvement of CAR T cells trafficking and delivery to the tumor site and how to solve the problem of tumor antigen heterogeneity.
Keywords: Adoptive cell therapy; CAR T cell; Challenges; Chimeric antigen receptor; Immunotherapy; Solid tumor.
Similar articles
-
Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.Front Immunol. 2022 Feb 8;13:830292. doi: 10.3389/fimmu.2022.830292. eCollection 2022. Front Immunol. 2022. PMID: 35211124 Free PMC article. Review.
-
Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.Mamm Genome. 2018 Dec;29(11-12):739-756. doi: 10.1007/s00335-018-9756-5. Epub 2018 Jul 9. Mamm Genome. 2018. PMID: 29987406 Review.
-
Engineering CAR-T Cells for Next-Generation Cancer Therapy.Cancer Cell. 2020 Oct 12;38(4):473-488. doi: 10.1016/j.ccell.2020.07.005. Epub 2020 Jul 30. Cancer Cell. 2020. PMID: 32735779 Review.
-
Engineered Cytokine Signaling to Improve CAR T Cell Effector Function.Front Immunol. 2021 Jun 4;12:684642. doi: 10.3389/fimmu.2021.684642. eCollection 2021. Front Immunol. 2021. PMID: 34177932 Free PMC article. Review.
-
Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors.Front Immunol. 2025 Jan 6;15:1489827. doi: 10.3389/fimmu.2024.1489827. eCollection 2024. Front Immunol. 2025. PMID: 39835140 Free PMC article. Review.
Cited by
-
Heme Oxygenase 1 (HO-1) as an Inhibitor of Trafficking of Normal and Malignant Hematopoietic Stem Cells - Clinical and Translational Implications.Stem Cell Rev Rep. 2021 Jun;17(3):821-828. doi: 10.1007/s12015-020-10083-w. Epub 2020 Nov 16. Stem Cell Rev Rep. 2021. PMID: 33196976 Free PMC article. Review.
-
The inhibitory efficacy of Ginsenoside Rg3 on proliferation and migration of colonic carcinoma cells through the JAK3/STAT5 signaling pathway.Discov Oncol. 2024 Nov 1;15(1):608. doi: 10.1007/s12672-024-01476-1. Discov Oncol. 2024. PMID: 39485563 Free PMC article.
-
NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development.Cells. 2021 Dec 1;10(12):3390. doi: 10.3390/cells10123390. Cells. 2021. PMID: 34943898 Free PMC article. Review.
-
Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.Stem Cell Rev Rep. 2021 Dec;17(6):2081-2106. doi: 10.1007/s12015-021-10246-3. Epub 2021 Sep 2. Stem Cell Rev Rep. 2021. PMID: 34472037 Free PMC article. Review.
-
JAK-STAT Domain Enhanced MUC1-CAR-T Cells Induced Esophageal Cancer Elimination.Cancer Manag Res. 2020 Oct 8;12:9813-9824. doi: 10.2147/CMAR.S264358. eCollection 2020. Cancer Manag Res. 2020. Retraction in: Cancer Manag Res. 2024 Jun 20;16:641-642. doi: 10.2147/CMAR.S483243. PMID: 33116840 Free PMC article. Retracted.
References
-
- Elahi, R., Khosh, E., Tahmasebi, S., & Esmaeilzadeh, A. (2018). Immune cell hacking: Challenges and clinical approaches to create smarter generations of chimeric antigen receptor T cells. Frontiers in Immunology, 9. https://doi.org/10.3389/fimmu.2018.01717 .
-
- Junghans, R. P., Ma, Q., Rathore, R., Gomes, E. M., Bais, A. J., Lo, A. S., et al. (2016). Phase I trial of anti-PSMA designer CAR-T cells in prostate Cancer: Possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response. The Prostate., 76(14), 1257–1270. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources